Abbott’s multipurpose disinfecting solution for contacts gets FDA OK
ABBOTT PARK, Ill. Abbott has received market clearance from the Food and Drug Administration for RevitaLens Ocutec, a multipurpose disinfecting solution for silicone hydrogel and conventional soft contact lenses.
"This advanced, next-generation solution establishes a new standard of disinfecting technology for contact lens wearers," stated Jim Mazzo, SVP Abbott Medical Optics. "Proper contact lens care, including a rub and rinse regimen using RevitaLens Ocutec, will help patients achieve clean and comfortable lenses while enhancing overall lens-wearing satisfaction."
RevitaLens Ocutec multipurpose disinfecting solution was developed in cooperation with silicone hydrogel, microbiology and chemistry experts and with input from more than 600 eye care professionals.
It is estimated that there are 125 million contact lens wearers worldwide. Multipurpose solutions represent the majority of systems used for the care of soft contact lenses. These are comprised of a single solution for the rinsing, cleaning, disinfection and storage of lenses, and typically are composed of a preservative, buffer system and other agents to aid in lens cleaning and comfort.
Key characteristics of RevitaLens Ocutec multipurpose disinfecting solution include:
- High micro-organism kill rates;
- Removes proteins from the lens surface;
- Effectively kills acanthamoeba and fusarium;
- Reduces corneal staining; and
- Minimizes the risk of eye complications.
Abbott plans to begin retail shipment of RevitaLens Ocutec multipurpose disinfecting solution in the United States in October. The product also has CE Mark approval in Europe.
Sun Pharma gets FDA approval for ALS generic
MUMBAI, India The Food and Drug Administration has approved a generic version of a drug for a devastating muscular disorder.
Sun Pharmaceutical Industries announced Tuesday the approval of riluzole hydrochloride in the 50-mg strength. The tablets are used to treat amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease.
The drug is a generic version of Sanofi-Aventis’ Rilutek, which has sales of around $50 million, according to Sun.
Cirrus targets ear-ringing with Tinnitex
COLD SPRING HARBOR, N.Y. Cirrus Healthcare Products has expanded its ear care offerings with a new product, slated to hit retail shelves in spring 2011.
Tinnitex is the first and only earplug to help relieve tinnitus, a condition that causes ringing in the ears, the company said. According to the Journal of Clinical Nursing, more than 50 million Americans suffer from tinnitus.
“Tinnitex gives the suffering consumer an option to the inconvenience of ear drops or the excessive amount of pills that consumers are tired of taking. The Tinnitex earplug is easy to apply and comfortable to wear and, at about $10 at retail for six pairs, provides affordable relief,” said Cirrus CEO Drew O’Connell.